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Chondrocalcinosis (CC) is a common cause of joint pain and arthritis that is caused by the deposition of calcium-
containing crystals within articular cartilage. Although most cases are sporadic, rare familial forms have been linked
to human chromosomes 8 (CCAL1) or 5p (CCAL2) (Baldwin et al. 1995; Hughes et al. 1995; Andrew et al. 1999).
Here, we show that two previously described families with CCAL2 have mutations in the human homolog of the
mouse progressive ankylosis gene (ANKH). One of the human mutations results in the substitution of a highly
conserved amino acid residue within a predicted transmembrane segment. The other creates a new ATG start site
that adds four additional residues to the ANKH protein. Both mutations segregate completely with disease status
and are not found in control subjects. In addition, 1 of 95 U.K. patients with sporadic CC showed a deletion of
a single codon in the ANKH gene. The same change was found in a sister who had bilateral knee replacement for
osteoarthritis. Each of the three human mutations was reconstructed in a full-length ANK expression construct
previously shown to regulate pyrophosphate levels in cultured cells in vitro. All three of the human mutations
showed significantly more activity than a previously described nonsense mutation that causes severe hydroxyapatite
mineral deposition and widespread joint ankylosis in mice. These results suggest that small sequence changes in
ANKH are one cause of CC and joint disease in humans. Increased ANK activity may explain the different types
of crystals commonly deposited in human CCAL2 families and mutant mice and may provide a useful pharma-
cological target for treating some forms of human CC.
Introduction
Deposition of calcium containing crystals in articular car-
tilage is a common pathological finding, with a prevalence
that rises sharply with age. Up to 40% of the elderly show
radiographic evidence of mineral deposition in their joints
(Dieppe and Watt 1985; Felson et al. 1989). In severe
cases, mineral deposits can trigger acute attacks of joint
pain and synovitis (pseudogout), or long-term structural
alterations and arthritis (chronic pyrophosphate arthrop-
athy) (Kohn et al. 1962; McCarty 1976; Doherty and
Dieppe 1988).
The most commonmineral deposits found in articular
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cartilage are crystals of calcium pyrophosphate dihy-
drate (CPPD) or basic calcium phosphate, including hy-
droxyapatite (HA). Metabolic diseases that elevate the
concentration of either calcium or pyrophosphate ions
can lead to CPPD crystal deposition (Doherty et al.
1991a; Jones et al. 1992). However, the causes of most
forms of chondrocalcinosis (CC) are still unknown.
Several kindreds have been described that segregate
CC as an autosomal dominant trait (van der Korst et
al. 1974; van der Korst and Geerards 1976; Gaucher
et al. 1977; Richardson et al. 1983; Doherty et al.
1991b; Baldwin et al. 1995; Andrew et al. 1999). In
these families, CPPD crystal deposition typically begins
in the 3rd and 4th decades, affects several joints, and
leads to arthropathy, pseudogout, or pseudo-osteo-
arthritis. Genetic linkage studies have mapped these fa-
milial forms of CC to two different major chromosome
regions, CCAL1 MIM 600668 on chromosome 8 and
CCAL2 MIM 118600 on chromosome 5 (Baldwin et
al. 1995; Hughes et al. 1995; Andrew et al. 1999).
In mice, a classical mutation called progressive an-
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kylosis is known to cause a severe form of generalized
joint calcification and arthritis (Sweet and Green 1981).
The mouse mutation behaves as an autosomal recessive
trait instead of an autosomal dominant one and leads
to accumulation of hydroxyapatite crystals rather than
CPPD crystals in articular cartilage and synovial fluid
(Hakim et al. 1984). Recent cloning and sequencing
studies have shown that progressive ankylosis is caused
by a nonsense mutation in a novel multiple-pass trans-
membrane protein that is highly conserved in verte-
brates. This protein alters levels of both intracellular
and extracellular pyrophosphate in cultured cells and
may act as a pyrophosphate transporter that stimulates
the elaboration of extracellular pyrophosphate from in-
tracellular stores (Ho et al. 2000).
The human homolog (ANKH [MIM 605145]) of the
mouse progressive ankylosis gene maps to chromosome
5, closely linked to D5S1954 (Ho et al. 2000). This
location places the gene within the critical region pre-
viously defined for both a British family and a French
family with CCAL2 (Hughes et al. 1995; Andrew et al.
1999). On the basis of the map location of ANKH and
its previously established role in pyrophosphate regu-
lation and joint calcification, we have tested whether
human patients with CC harbor sequence changes in
ANKH. The previously described British and French
families have small amino acid alterations in ANKH
that segregate completely with disease status. An ad-
ditional 1 of 95 sporadic patients shows a single amino
acid deletion in the ANKH protein. Reconstruction of
each mutation in a full-length ANK expression con-
struct followed by in vitro tissue culture assays showed
that the altered human proteins have significantly more
activity than the truncated protein of mice with pro-
gressive ankylosis. These results show that some forms
of human CC are caused by mutations in the ANKH
gene and that these mutations may lead to increased
rather than decreased ANKH function.
Material and Methods
Mutation Screening
ANKH gene sequences were amplified from blood cell
genomic DNA prepared from two previously described
families with CCAL2, from 95 patients with sporadic
CC diagnosed by x-ray examination and from 200 un-
affected control subjects. Forward and reverse primer
pairs were designed to amplify all 12 exons and flanking
splice sites of theANKH gene (primers and amplification
conditions available upon request). Amplified products
were purified from agarose gels using Wizard columns
(Promega) and were sequenced using the BigDye ter-
minator cycle protocol (ABI). All heterozygous base pair
changes were confirmed by independent amplifications,
sequencing reads on both strands, or by cloning and
resequencing of individual subclones from the bulk am-
plification reactions.
The sequence changes found in exon 1 and exon 12
were reanalyzed in 190 control chromosomes by am-
plification and direct sequencing. For the –11CT change
in exon 1, we used flanking primers 5′-gatctttgttgtgtggg-
agg-3′ and 5′-cacccgaccaaatgtttcagg-3′. For the change in
exon 12, we used flanking primers 5′-gaaggtttaagcctaca-
gtga-3′ and 5′-tgatgccgaagtgtcatcct-3′. The sequence
change in the French family creates a new Hga1 restric-
tion site in exon 2. A 389-bp PCR product spanning
this mutation was amplified using an initial round of
PCR with forward primer 5′-catgagatgcaccctataagctac-
3′ and reverse primer 5′-gaaattgccaaagctagattcgtc-3′, fol-
lowed by a second round of amplification with the same
forward primer and a nested reverse primer, 5′-ttgccaaag-
ctagattcgtca-3′. Hga1 digestion of these products re-
sulted in the predicted band of 389 bp in unaffected
family members and 107 unrelated control subjects and
resulted in the expected additional smaller fragments of
213 bp and 176 bp in all affected patients carrying the
missense mutation.
In Vitro Translation and Mass Determination
The effect of the –11CT mutation was assessed by
first subcloning the wild type and mutant exon 1 se-
quences in the TA cloning vector (Invitrogen), amplifying
with primers that contained an upstream T7 RNA poly-
merase promoter (5′-taatacgactcactatagggagcggcagca-3′)
and a downstream termination codon (5′-acacccgaccaaa-
tgtttaagg-3′), and then testing the size of the encoded
proteins using a TNT-coupled in vitro transcription and
rabbit reticulocyte translation system (Promega). We
concentrated, desalted, and removed detergents from the
peptide product with 10 ml C18 ZipTips (Millipore), and
we analyzed the final eluted peptide using a Termofin-
nigan LCQ deca Electrospray Ionization Mass Spec-
trometer (ESI). The wild-type sequence should generate
a polypeptide of 67 amino acids in this system (estimated
Mw: 7303). If the novel upstream ATG sequence is rec-
ognized as a new translational start site, the mutant se-
quence should generate a larger polypeptide with four
additional residues added to the amino terminus (esti-
mated Mw: 7664).
Cell Culture and Pyrophosphate Determination
Each of the human sequence changes was recreated
in the previously described full-length ANK expression
construct (pCMV-ANK) (Ho et al. 2000). The French
M48T mutation was generated using the Stratagene
QuickChange site-directedmutagenesis protocol. Briefly,
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25–45 bp forward and reverse primers were designed
that completely overlap and incorporate the desired se-
quence change (forward: 5′-gatgcagtagaaaCgctggccagc-
tac-3′; reverse: 5′-gtagctggccagcGtttctactgcatc-3′). The
original template was digested with DpnI and the cir-
cular PCR product was transformed into electrocom-
petent DH10B cells. Finally, the modified ANK cDNA
insert was removed by restriction digest and was ligated
into a freshly cut vector to ensure that experimental re-
sults were not influenced by base-pair changes incor-
porated into the vector during PCR.
The British –11CT sequence change was recreated
by inserting 18 bp of the mutant 5′ UTR flanking hu-
man sequence into the pCMV-ANK vector (forward
primer: 5′-cgcggatccggtcagcccATGgcggggactATGgtga-
aattcccggcgc-3′; reverse primer: 5′-cgcgaattcttactcattttc-
ttctctcatct-3′) via PCR. A control construct carrying the
wild-type human 5′ UTR was generated in parallel (for-
ward: 5′-cgcggatccggtcagcccacggcggggactATGgtgaaa-
ttcccggcgc-3′; reverse: 5′-cgcgaattcttactcattttcttctctca-
tct-3′). The control construct was called “pCMV-
hum5ANK.” Finally, the E490del mutation was rec-
reated in the pCMV-hum5ANK control vector via site-
directed mutagenesis, as described for the French M48T
mutation (forward primer: 5′-cagacatcgtagagatgagagaa-
aatgagtaagaattctgcag-3′; reverse primer: 5′-ctgcagaattctt-
actcattttctctcatctctacgatgtctg-3′). All constructs were se-
quenced across the entire open reading frame to confirm
that the predicted sequence alterations had been made
without introducing undesired mutations.
COS-7 cells were transfected with 7 mg of DNA using
fugene 6 reagent, and cells from three 10 cm plates were
scraped and pooled 28–34 h later. PPi was extracted
from cells in percholoric acid, as described elsewhere
(Ho et al. 2000), and PPi concentrations were measured
using a coupled enzymatic assay (Doherty et al. 1991a;
Terkeltaub et al. 1994) containing 57 mM Tris, 5.2 mM
magnesium acetate, 4 mMNADP, 18.6 mM glucose 1,6-
diphosphate, 7.5 mM UDPG, 0.4 units glucose-6-phos-
phate dehydrogenase, 0.057 units phosphoglucomutase,
0.136 units UDPG pyrophosphorylase, and tritiated
UDPG (0.04 mCi: specific activity 25 Ci/mmol), in 100
ml and 40 ml of sample or PPi standard (0–400 pmoles).
After 1 h at 37C, 0.2 ml of 4% charcoal suspended in
50 mM Tris acetate was added to each sample to sep-
arate unreacted substrate from labeled 6-phosphoglu-
conate. Samples were vortexed and incubated at 4C for
10 min before centrifugation at 2,000g for 10 min at
4C. Supernatants (0.2 ml) were placed in 5 ml of scin-
tillation fluid and were counted. The effects of each se-
quence variant were compared to matched wild-type in-
ternal controls performed in parallel in each experiment,




ANKH maps within the overlapping 5p candidate re-
gion previously defined for two CCAL2 families
(Hughes et al. 1995; Andrew et al. 1999; Ho et al. 2000).
To test for sequence changes in human CC, we amplified
each of the 12 ANKH coding exons from family mem-
bers in the French (Andrew et al. 1999) and British
(Hughes et al. 1995) kindreds with CCAL2 (fig. 1). All
affected individuals of the French family were hetero-
zygous for a thymine-to-cytosine base change (143TrC)
in exon 2 (fig. 2). This missense mutation substitutes
threonine for methionine in a predicted transmembrane
domain at a position that is absolutely conserved in the
ANKH protein over 400 million years of evolution, from
fish to mammals (Ho et al. 2000; Nurnberg et al. 2001).
In contrast, all of the affected members of the U.K. kin-
dred were heterozygous for a cytosine-to-thymine base
change (–11CrT) located 11 bp upstream of the normal
ATG initiation codon (fig. 2). This change generates an
alternative ATG initiation codon and is predicted to add
four amino acids to the highly conserved N-terminus of
the ANKH protein. Reconstruction of the –11CT mu-
tation showed that the new upstream ATG sequence is
recognized as a translational start in a rabbit reticulocyte
translation system. ESI mass spectrometry confirmed
that the ANKH polypeptide translated from the mutant
expression construct is 344 Da larger than the polypep-
tide from the wild-type construct (fig. 3). In both the
French and British kindreds, the mutation resides on the
disease allele and segregates completely with CC (fig. 1).
Neither of the mutations was found in DNA samples
from unaffected family members or in 200 chromosomes
from unaffected control individuals.
To test whether ANKH sequence changes may also be
involved in sporadic forms of CC, we sequenced ANKH
coding exons from 95 British patients with CC. One
patient who presented with late-onset polyarticular CC
with structural arthropathy of both knees had a 3-bp
deletion, in exon 12, that deletes a glutamate residue
(E490del) three amino acids from the highly conserved
carboxyl terminus of the ANKH protein (fig. 2). This
deletion was not seen in any of the control chromo-
somes. However, analysis of DNA from two other avail-
able family members showed that a sister and son of the
index case were also heterozygous for the same 3-bp
deletion (fig. 1). Although neither had demonstrable CC,
the sister had undergone bilateral total knee replacement
surgery for “osteoarthritis.” Her preoperative radio-
graphs were unavailable, but there was no CC on her
pelvis or hand radiographs. Knee radiographs of the son
were normal, but at the age of 42 years, he may not yet
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Figure 1 Families with CC mutations in ANKH. A, Affected family members of the British family with CCAL2 have one or more benign
febrile fits as children and develop florid polyarticular CC in their 3rd or 4th decade (Doherty et al. 1991b). B, and C, Radiographs of the
hand of a female family member show gross calcification of the metacarpophalangeal joints and extensive CC in both the triangular ligament
fibrocartilage (asterisk) and articular cartilage of nearly all wrist joints (arrowhead). D, Members of the previously described French family
with CCAL2 develop CC in many joints of the legs, arms, and spine by age 35 (Gaucher et al. 1977). E, Radiographs of the knee of a 56-
year-old man show pronounced calcific deposits of the femoropatellar articular cartilage. F, and G, Wider screening of sporadic cases identified
a 79-year-old man with CC affecting his medial tibiofemoral compartment (G), wrist triangular ligament, symphysis pubis, and hips. His sister
has had bilateral knee replacements for “osteoarthritis.” In all three pedigrees, black shading represents affected status. All affected family
members were heterozygous for different ANKHmutations (see text), and all unaffected family members were homozygous for wild-typeANKH
alleles with the exception of the youngest member of the third pedigree, who was heterozygous for ANKH mutations but not yet old enough
to reliably determine CC status (gray box, panel F).
display CC. No further mutations were identified in 95
patients with sporadic CC.
In Vitro Functional Assays
Previous studies have shown that overexpression of
wild-typeANK in COS cells decreases intracellular levels
of pyrophosphate (PPi) and increases extracellular py-
rophosphate, most likely by transport via the multiple-
pass transmembrane ANK protein (Ho et al. 2000). This
is biologically relevant, because PPi can both promote
deposition of CPPD crystals (as a constituent ion) and
inhibit deposition of hydroxyapatite crystals (by binding
to the surface of calcium phosphate crystals and blocking
further crystal growth) (Kohn et al. 1962; Fleisch 1981;
Rachow and Ryan 1988). The nonsense mutation in
progressive ankylosis mice truncates the ANK protein
and greatly reduces its ability to alter pyrophosphate
levels in transfected tissue culture cells (Ho et al. 2000).
To compare the effect of the mouse and human muta-
tions, we reconstructed the –11CT, M48T, and E490del
mutations and tested their effect on pyrophosphate levels
in transfected COS cells. As expected, full-length wild-
type ANK caused a significant reduction in intracellular
pyrophosphate (58  5% of levels seen in cells trans-
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Figure 2 Identification and location of ANKH mutations. Three different mutations were identified in DNA sequence traces of the families
with CC. The –11CT change creates a novel ATG initiation codon in the 5′ untranslated region of ANKH. A thymine-to-cytosine transition at
position 143 leads to a substitution of threonine for methionine. Deletion of three base pairs removes a glutamate codon near the carboxy
terminus of the ANK protein.
Figure 3 Mass spray analysis of ANKH polypeptides generated
from wild-type and mutant constructs. A, and B, The presence of the
–11CT mutation in the 5′ UTR of ANKH creates a new in-frame ATG
and directs translation of a predominantly 7,729 Da ANK polypeptide
compared to a smaller, 7,385 Da form translated from the wild-type
allele.
fected with vector only control, inP ! .0001 np 23
experiments). The activity of the mouse ank mutant al-
lele was sharply reduced (24%  14% of the decrease
seen with wild type ANK, P!.0001; 23 experiments). In
contrast, 11CT, M48T, and E490del mutations had
mean activities that were 148% 33%, 101% 25%,
and 109%  12% of matched wild-type ANK values
(mean SEM percent reduction of intracellular PPi con-
centration compared to cells transfected with wild type
ANK, P values of .18, .97, and .47 compared to wild
type ANK; and P values of .016, .018, .003 compared
to the mouse mutant form of ANK in np13, 18, and
13 experiments, respectively).
Discussion
None of the CC mutations presented here appear to be
null mutations. Their differing location in the ANKH
gene may help explain important phenotypic differences
between the human CCAL2 families and the mouse pro-
gressive ankylosis mutant. For example, the U.K. family
is unique in that adult-onset CC is preceded by repeated
benign fits during childhood. The extra 4-aa extension
found in the U.K. family may produce a new activity or
interaction in neural cells, a known site of ANK ex-
pression in mice and humans (Ho et al. 2000).
Although the recessive mouse mutation causes early
and widespread deposition of hydroxyapatite mineral
in articular cartilage and synovial fluid (Hakim et al.
1984), the dominant human mutations described here
lead to slow adult-onset deposition of calcium pyro-
phosphate dihydrate (CPPD) crystals (Gaucher et al.
1977; Doherty et al. 1991b). The different crystal types
formed in the mouse and human diseases and the slower
time course of the human disease may result from dif-
fering effects of the mutant alleles on pyrophosphate
levels (fig. 4). The mouse nonsense mutation truncates
the ANK protein, sharply reduces protein activity in
vitro, and causes a decrease in pyrophosphate levels
outside cells. This drop in PPi levels would eliminate a
normal physiological block to hydroxyapatite forma-
tion (Fleisch 1981) and would lead to the widespread
deposition of hydroxyapatite mineral seen in mutant
mice (Ho et al. 2000). In contrast, the human alleles
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Figure 4 Summary of known ANKH mutations and model of
different effects on hydroxyapatite and CPPD mineral deposition. A,
The locations of the new CC mutations (red) are compared to pre-
viously identified mutations responsible for mouse progressive anky-
losis (blue) and human craniometaphyseal dysplasia (green). B, Pre-
vious studies suggest that the ANK multiple-pass transmembrane
protein may transport pyrophosphate across the membrane (Ho et al.
2000). The wild-type protein promotes accumulation of extracellular
pyrophosphate from intracellular stores. Extracellular pyrophosphate
acts as an inhibitor of hydroxyapatite deposition, normally preventing
mineralization of articular cartilage (Fleisch 1981). Loss of ANK func-
tion in progressive ankylosis mice leads to a decrease in extracellular
pyrophosphate and results in deposition of hydroxyapatite in joints.
In contrast, the dominant human CC mutations lead to excess extra-
cellular pyrophosphate, eventually stimulating precipitation of calcium
and pyrophosphate as CPPD crystals.
cause small amino acid changes instead of truncations,
and each of these alleles shows a high level of activity
compared to the mouse mutation in vitro. We have only
measured intracellular pyrophosphate levels in the
transfected COS cells. However, given the substantial
activity of the CCmutations in the COS cell experiments
and the known ability of wild-type ANK to increase
extracellular pyrophosphate levels (Ho et al. 2000), we
think it likely that the human CC mutations will also
lead to reciprocal small increases in extracellular py-
rophosphate. Although the total difference in activity
between wild-type ANK and the CC alleles appears to
be minor, even a small increase in total ANK activity
may be sufficient to lead to ectopic crystal formation
over the course of many years. Elevated pyrophosphate
concentrations can trigger direct precipitation of cal-
cium and pyrophosphate ions, leading to deposition of
CPPD crystals instead of hydroxyapatite. This effect is
also seen in several other metabolic diseases that raise
pyrophosphate levels including hypomagnesaemia, hae-
mochromatosis, and hypophosphatasia (Doherty et al.
1991a; Jones et al. 1992). The combined data and the
dominant inheritance of CC suggest that the human
mutations might be gain-of-function alleles that lead to
slow accumulation of pyrophosphate in vivo.
Previous studies have shown that extracellular py-
rophosphate levels are elevated in synovial fluid of the
British family, a result fully consistent with our working
model of increased ANK activity caused by the CC mu-
tations (Doherty 1991b). In contrast, previous studies
have shown that intracellular pyrophosphate levels are
increased in cultured fibroblasts and lymophocytes of
patients from the French family, a result that differs
from the effect seen when the French mutant form of
ANK is transfected into cultured COS cells in the cur-
rent studies. We note, however, that the cell types,
growth conditions, and serum supplementation levels
are markedly different in the two types of experiments.
Pyrophosphate levels are known to respond to changes
in culture conditions (Rosenthal et al. 1991), and recent
studies suggest that ANK expression is also markedly
sensitive to changes in cytokines and serum levels (Guo
et al. 2001). An important goal for the future will be a
more detailed characterization of the effects of the
mouse and human mutations on both intracellular and
extracellular pyrophosphate levels in stable cell lines, in
articular cartilage cells, and in synovial fluids. We are
in the process of recreating the human mutations in
mouse animal models to facilitate a more detailed com-
parison of their effects on different tissues under uni-
form conditions.
The sequence changes reported here provide the first
evidence that some forms of human CC are due to mu-
tations in ANKH.Our studies have only examined cod-
ing region changes in the gene. Changes in cis-acting
regulatory sequences might also lead to increased
ANKH activity. It will be important to test in the future
whether additional cases of CCmay be due tomutations
in regulatory regions of ANKH or to induction of
ANKH activity by cytokines or growth factors (Guo et
al. 2001) in joint regions. Other mutations in ANKH
have recently been reported in patients with craniom-
etaphyseal dysplasia (CMD [MIM 123000]), a domi-
nant skeletal disease characterized by hyperostosis and
sclerosis of the skull and long bones (Nurnberg et al.
2001; Reichenberger et al. 2001). The clustering of
CMDmutations in a single predicted loop of the ANKH
protein suggests that they are specialized alleles that
alter transport specificity or activity (fig. 4). The current
data indicate that distinct mutations in the ANKH pro-
tein can lead to CPPD deposition. The dual role of py-
rophosphate as both an inhibitor of hydroxyapatite
deposition and a promoter of CPPD deposition may
Pendleton et al.: ANKH Mutations in Chondrocalcinosis 939
help explain how different mutations in the same gene
can lead to formation of different types of crystal.
Agents that inhibit ANKH transport activity, such as
the anion transport inhibitor probenecid (Ho et al.
2000; Rosenthal and Ryan 1994), might provide a use-
ful therapeutic approach for lowering pyrophosphate
levels and reducing CPPD deposition in a subset of pa-
tients with CC. However, any effective therapy is likely
to depend upon maintaining extracellular PPi within a
narrow physiological range, given that we now know
that an abnormal increase in extracellular PPi/ANKH
function leads to pathological CPPD formation,
whereas an excessive decrease in extracellular PPi/
ANKH function may lead to pathological hydroxyapa-
tite formation.
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